September 2025
-
Story
test content -
Featured NewsTest
-
Story About Novartis Access to Healthcare
Test story page for non english content -
Story
test story -
Story
Test - Story - ContentSync - Translated content pulled from Repository -
Story About Novartis
Test Content
-
Press releaseNovartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a…
-
Story About Novartis Access to Healthcare
test story content
August 2025
-
Press releaseNovartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle painV-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85%…
-
Press releaseNew Novartis ESC data highlights strength of cardiovascular portfolioTwo VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing…
-
Press releaseNovartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failureIanalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients…
-
Press releaseNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s diseaseAd hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s…